Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of HER2,ERBB2. The page also collects GeneMedi's different modalities and formats products for HER2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the HER2 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

Target IDGM-T14597
Target NameHER2
Gene ID2064
Gene Official NameERBB2
Gene AliasCD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, Diagnostics Biomarker, INN Index, Cytokine Target, Immuno-oncology Target


Pre-made HER2-specific INN-index biosimilar (antibody&conjugates)-cinrebafusp alfa, Gancotamab, Zanidatamab, zanidatamab zovodotin, Runimotamab, Margetuximab, Disitamab, Pertuzumab, Timigutuzumab, Fidasimtamab, Anbenitamab, tezatabep matraxetan, trastuzumab beta, Trastuzumab, trastuzumab emtansine, Marstacimab, trastuzumab duocarmazine, Zenocutuzumab, disitamab vedotin, Coprelotamab, ertumaxomab, trastuzumab deruxtecan

Anti-HER2 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-INN-780Pre-Made Cinrebafusp Alfa P Alfaiosimilar, Bispecific, Anti-ERBB2/HER2;TNFRSF9 Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 therapeutic antibodycinrebafusp alfaERBB2/HER2;TNFRSF9BispecificINN mab
GMP-Bios-ab-230Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyGancotamabERBB2/HER2scFvINN mab
GMP-Bios-ab-639Pre-Made Zanidatamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;ERBB2/HER2 Antibody: Anti-CD340/HER-2/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyZanidatamabERBB2/HER2;ERBB2/HER2Bispecific/biparatopicINN mab
GMP-Bios-INN-1055Pre-Made Zanidatamab Zovodotin B Zovodotiniosimilar, Bispecific/Biparatopic, Anti-ERBB2/HER2;ERBB2/HER2 Therapeutic/Biparatopic Antibody Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2zanidatamab zovodotinERBB2/HER2;ERBB2/HER2Bispecific/biparatopicINN mab
GMP-Bios-ab-500Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibodyRunimotamabERBB2/HER2;CD3EBispecific mAbINN mab
GMP-Bios-ab-335Pre-Made Margetuximab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyMargetuximabERBB2/HER2Whole mAbINN mab
GMP-Bios-ab-148Pre-Made Disitamab biosimilar, Whole mAb ADC, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyDisitamabERBB2/HER2Whole mAb ADCINN mab
GMP-Bios-ab-439Pre-Made Pertuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyPertuzumabERBB2/HER2Whole mAbINN mab
GMP-Bios-ab-576Pre-Made Timigutuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyTimigutuzumabERBB2/HER2Whole mAbINN mab
GMP-Bios-ab-667Pre-Made Fidasimtamab biosimilar, Whole mAb, Anti-PDCD1/PD-1;ERBB2/HER2 Antibody: Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyFidasimtamabPDCD1/PD-1;ERBB2/HER2Bispecific Whole mAbINN mab
GMP-Bios-ab-023Pre-Made Anbenitamab biosimilar, Bispecific mAb: Anti-ERBB2 (Domain II);ERBB2 (Domain IV) therapeutic antibodyAnbenitamabERBB2 (Domain II);ERBB2 (Domain IV)Bispecific/biparatopicINN mab
GMP-Bios-INN-1021tezatabep matraxetanERBB2Radiolabelled peptideINN mab
GMP-Bios-INN-1030Pre-Made Trastuzumab Beta Biosimilar, Whole Mab, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibodytrastuzumab betaERBB2/HER2Whole  mAbINN mab
GMP-Bios-ab-593Pre-Made Trastuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyTrastuzumabERBB2/HER2Whole mAbINN mab
GMP-Bios-INN-1033Pre-Made Trastuzumab Emtansine Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugatetrastuzumab emtansineERBB2/HER2Whole mAb ADCINN mab
GMP-Bios-ab-336Pre-Made Marstacimab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyMarstacimabERBB2/HER2Whole mAbINN mab
GMP-Bios-INN-1032Pre-Made Trastuzumab Duocarmazine Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugatetrastuzumab duocarmazineERBB2/HER2Whole mAb ADCINN mab
GMP-Bios-ab-645Pre-Made Zenocutuzumab biosimilar, Bispecific mAb, Anti-ERBB3/Erbb-3;ERBB2/HER2 Antibody: Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyZenocutuzumabERBB3/Erbb-3;ERBB2/HER2Bispecific mAbINN mab
GMP-Bios-INN-804Pre-Made Disitamab Vedotin Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugatedisitamab vedotinERBB2/HER2Whole mAb ADCINN mab
GMP-Bios-ab-119Pre-Made Coprelotamab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyCoprelotamabERBB2/HER2Whole mAbINN mab
GMP-Bios-INN-845Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyertumaxomabCD3E;ERBB2BispecificINN mab
GMP-Bios-INN-1031Pre-Made Trastuzumab Deruxtecan Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugatetrastuzumab deruxtecanERBB2/HER2Whole mAb ADCINN mab



Pre-made anti-HER2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-HER2 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-HER2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T14597-AbAnti-HER2/ERBB2 monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibody, Diagnostic target antibody, Cytokine antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×